Fertilization Clinical Trial
Official title:
Evaluation of the Impact of Vitrification on the Reproductive Performance and Potential of Human Oocytes
The purpose of this study is to determine the rate of cryosurvival of mature oocytes following vitrification, and to then compare the reproductive potential of vitrified oocytes relative to those which have not been cryopreserved.
This study will recruit patients from the NY/NJ/CT/eastern PA area only.
Cryopreservation of human oocytes has a great potential to preserve or extend fertility in
the face of disease whose treatment would result in a loss of ovarian function. (malignancy,
severe autoimmune disease, etc.). It would also provide a means of quarantining oocytes to
be used in oocyte donation to provide the lowest possible risk of infection.
There are two methods for storage of oocytes: slow freezing or vitrification. Slow freezing
is the conventional method and has been successfully used for embryos since 1983 and more
recently for oocytes. Recent reports indicate that vitrification may be more successful than
slow freezing. However, the technique has not been rigorously validated to date. The aim of
this study is to determine the rate of cryosurvival of mature oocytes following
vitrification, and to then compare the reproductive potential of vitrified oocytes relative
to those which have not been cryopreserved.
Patients will undergo ovarian stimulation for in vitro fertilization (IVF) according to the
protocol recommended by their primary doctor. After retrieval, mature oocytes will be
divided in half. One half will undergo vitrification, immediate thaw and intracytoplasmic
sperm injection (ICSI). The other half will undergo just ICSI. All embryos will then develop
on identical culture until day 3 or day 5. Prior to transfer, the best embryo from each
group will undergo biopsy for genetic fingerprinting. The patient will have a 2 embryo
transfer (one from each group). All extra embryos will be biopsied for pre-implantation
genetic diagnosis (PGD) prior to being cryopreserved. If the patient becomes pregnant, we
will follow up with an additional blood draw at approximately 9 weeks gestation and buccal
swabs after the delivery of the infant(s).
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01558141 -
Follicular Flushing
|
N/A | |
Not yet recruiting |
NCT04519918 -
Clinical Application of Artificial Oocyte Activation Technique (AOA) in ART
|
N/A | |
Recruiting |
NCT03810001 -
Mechanical Stimulation Improve the Fertilization in ICSI Cycle
|
N/A | |
Not yet recruiting |
NCT04523103 -
Artificial Assisted Activation Following in Fertilization Failure
|
N/A | |
Completed |
NCT00340587 -
Human Sperm Binding to Transgenic Mouse Eggs
|
||
Completed |
NCT00598208 -
A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)
|
Phase 2 | |
Not yet recruiting |
NCT06433518 -
BEst Size for Ovulation Triggering in Poseidon 4 Patients (BEST 4 Study)
|
||
Completed |
NCT02913781 -
Polar Body Removal Before ICSI for Oocyte Activation in Previous Fertilization Failure Cases
|
N/A | |
Recruiting |
NCT04537481 -
Lipidic Differences of Sperm Between Normal and Low Fertilization Patients
|
N/A |